Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 13/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486625 | 1.00 | SLC18A2 (1.00) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL17486623 | 1.00 | SLC18A2 (1.00) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL17486632 | 0.95 | SLC18A2 (1.00) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL19484640 | 0.95 | SLC18A2 (1.00) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL17486594 | 0.95 | SLC18A2 (1.00) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL17486624 | 0.95 | SLC18A2 (1.00) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL17486636 | 0.93 | SLC18A2 (0.87) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL17485175 | 0.93 | SLC18A2 (0.87) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL17485171 | 0.93 | SLC18A2 (0.87) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 | |
| SCHEMBL17477247 | 0.93 | SLC18A2 (1.00) | SLC18A2SLC6A3HTR2AHSD17B10MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | SLC18A2 1/4885SLC6A3 4/4885HTR2A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.